We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca’s, Merck’s Lynparza Shows Success Against Early Breast Cancer
AstraZeneca’s, Merck’s Lynparza Shows Success Against Early Breast Cancer
AstraZeneca’s (AZ) and Merck’s blockbuster cancer drug Lynparza (olaparib) has made a strong showing in a phase 3 trial evaluating it as an adjuvant treatment for an early form of breast cancer, according to early results from the study.